Last Updated on September 22, 2025 by The Health Master
Form 483
The US Food and Drug Administration (USFDA) completed an audit of Aurobindo Pharma at its manufacturing site in Bachupally, Telangana and issued a Form 483 with 8 observations.
But is this good or bad for the company and for the pharma sector?
What Is a USFDA Form 483?
The USFDA conducts drug manufacturing audits to determine whether a facility complies with Current Good Manufacturing Practice (CGMP) regulations, basically a mandated physical and health check of the medicine-making environment.
If the USFDA inspectors find conditions or practices that may be violating the cGMP standards, they’re obligated to call them out.
Form 483 is a notification of sorts.
It constitutes a list of violations or deviations from compliance regulations, but it’s not a death sentence and not legally binding.
It’s simply a notification by the USFDA to the management of the facility that they have observed certain items that need to be addressed, and it’s expected that a timely and thorough explanation will be provided in response to the findings.
What Did Aurobindo Pharma Receive Form 483 For?
Aurobindo Pharma‘s inspection focused on Unit-XII, which is responsible for oral solids and injectable drugs, and the observations were compiled over two weeks.
According to Aurobindo Pharma, however, the eight observations were “procedural in nature.”
This means that they are more likely related to documentation and process than to significant failures in the quality of drugs or ingredient exposure.
- Oral Solids/Injectables: Coverage of two different drug types shows that the examination was thorough.
- Procedural in Nature: While any Form 483 is serious, if these observations are indeed procedural in nature, this is less severe than any finding related directly to drug quality.
- Time Sensitivity for Response: Anytime a company receives a Form 483, time is of the essence to respond with context; Aurobindo Pharma has to reply in writing quickly.
Why It Matters
This is an important reminder that even top companies in pharma are being audited constantly.
Results like this serve to remind all potential patients that drugs approved for market come from consistently regulated environments.
When such news emerges, investors scramble to determine what it means for stock movement.
Form 483 serves as a precursor to potential negativity down the line if it’s not addressed rapidly (and sometimes even if it is).
“Procedural” is a good thing, but it can still hold up new drug applications or impact current product supply chains.
Pharma companies operate in a heavily regulated world; nothing moves without regulatory compliance.
Therefore, significant investments occur for quality control systems and USFDA audit preparation so that similar observations don’t get made.
Q: What happens when a Form 483 response is not satisfactory?
A: When a Form 483 response is not sufficient, further action can be taken by the USFDA including sending a Warning Letter which outlines serious transgressions and what might happen should such findings not be resolved. In extreme cases, an Import Alert can be issued which prevents an entity’s products from entering the US market at all.
USFDA issued Form 483 to Alembic Pharma with 1 observation
USFDA issued Form 483 with two observations to Aurobindo for API plant
USFDA issued Form 483 with 5 observations to Alembic
USFDA issued Form 483 with 7 observations to Dr Reddy’s
USFDA issued Form 483 with 4 observations to Shilpa Medicare
USFDA concludes inspection at Granules India with zero observations
Drug recall: Unichem recalls Cyclobenzaprine HCL Tablets
Govt. amends Uniform Code for Marketing Medical Devices
Govt to amend Clinical Trials Rules to speed up approvals
NPPA fixed retail price of 42 formulations: August 2025
New Draft Standards for TB IVD Medical Devices: CDSCO
Drug alert: 143 drug samples declared as NSQ in July 2025
Key Notes on Revised Schedule M: API Part-6
USFDA inspection: At Sun Pharma with 8 observations: Halol
